We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
25/2/2021 16:30 | It's time that GSK went into medicinal cannabis products! Just look at MXC and KNB and the debut of Cellular Goods tomorrow. I wonder if this possibility has had any serious consideration??????? | fez77 | |
25/2/2021 16:21 | Will let you know when I finished buying, something I spotted. | montyhedge | |
25/2/2021 16:19 | Spud I reckon GSK could have a 5 billion bonus up they sleeve, early days yet. | montyhedge | |
25/2/2021 16:17 | Does it matter no profit in covid vaccine anyway, ask Astra. | montyhedge | |
25/2/2021 15:44 | GlaxoSmithKline Covid-19 Antibody Study Didn't Meet Primary Endpoint 25/02/2021 12:29pm Dow Jones News GlaxoSmithKline PLC said Thursday that a phase-2 trial evaluating the use of a monoclonal antibody in Covid-19 patients didn't meet the primary endpoint when tested on patients of all ages. The drug, which is named otilimab, failed to achieve significant improvements in keeping patients free of respiratory failure 28 days after treatment when paired with the existing standard of care, the British pharmaceutical giant said. The study, however, did prove that treatment with otilimab was effective in patients 70 years and older when combined with the existing standard of care. As a result, the company said it will amend the study to expand its investigation in this age group and confirm the findings. spud | spud | |
25/2/2021 15:01 | I'm in seems a good price. Could go lower of course but you never know. Average PE of FTSE100 companies that have a PE tends to be about 20 So potentially price could double. Or alternatively profits could half. | netcurtains | |
25/2/2021 14:57 | Azn p/e 40.7Gsk p/e 10.5Based on 2020 fy results eps and current share price. | coxsmn | |
25/2/2021 14:47 | Mainly down to (Miss) Management (aka EW). spud | spud | |
25/2/2021 13:46 | sp valuation gap between gsk and azn is astounding | coxsmn | |
25/2/2021 11:27 | Ah cheers mate. This Test sounds a blast. | geckotheglorious | |
25/2/2021 11:27 | More4 from 1pm. Shows 1 day behind unfortunately. spud | spud | |
25/2/2021 11:25 | Montie, Why are you bashing Buywell3 for being on the wrong thread when you persistently repeat yourself on the AZN thread! Do everyone a favour and keep your comments here where it is percieved that you may have a holding for income? It would be good manners if you stopped mocking people for losing money on AZN, especially 'the boys that bought at 9,200' No need for it at all. | beckers2008 | |
25/2/2021 11:24 | Goodness me. Where's the best place to watch the highlights please spud? | geckotheglorious | |
25/2/2021 11:23 | Should have had a spoiler alert on that! Was planning on watching highlights this PM. spud | spud | |
25/2/2021 11:12 | It looks like the wicket has exploded. Lots of sand/dry mud forming pot holes. England lost 2 wickets already | tradermichael | |
25/2/2021 10:52 | TraderMichael. Wow India 11/7 for 6..England all out for smalls.. What's wrong with the pitch they're currently playing on? Is it very humid/wet where they are? | geckotheglorious | |
25/2/2021 09:54 | Nice to see though TM! | spyder | |
25/2/2021 09:43 | Sorry, wrong thread! | tradermichael | |
25/2/2021 09:43 | India 117 for 6 | tradermichael | |
25/2/2021 08:37 | Your on the wrong thread. This is GSK not Astra. | montyhedge | |
25/2/2021 08:02 | Looks like Covid-19 Variants are here to stay so : AZN are looking at using nasal spray vaccines ( like flu) Also oral vaccine tablets Also vaccine skin patches Strain on NHS resources re vaccinations continuance twice or thrice yearly is clearly not going to be a workable option in a year round 24/7 Covid-19 world | buywell3 | |
25/2/2021 07:31 | FTSE 100 spreads showing decent pre- trading gains for the first time since we found a 1200 floor ( to add to a decent session yesterday afternoon and across the pond) . If GSK wants to find escape velocity from 1200 it better make a move this morning after several failures earlier this week. | stewart64 | |
24/2/2021 20:21 | The correlation between AZN and GSK recently is there to see It is currently a SECTOR problem The massive amount of work and costs associated with manufacturing vaccines for Covid at prices the world can afford is imo hurting other lines and perhaps some are seeing this continuing Plus Debts are now seen as a future problem | buywell2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions